Bristol-Myers Squibb’s Promising Phase 3 Study on Deucravacitinib for Sjögren’s Syndrome

Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.

Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren’s Syndrome (POETYK SjS-1)’. The study aims to assess the safety and efficacy of Deucravacitinib in treating adults with active Sjögren’s Syndrome, a chronic autoimmune condition. This research is significant as it could lead to new treatment options for a condition that currently has limited therapeutic solutions.

Intervention/Treatment: The study is testing Deucravacitinib, a drug designed to manage symptoms of Sjögren’s Syndrome. Participants will receive either one of two doses of Deucravacitinib or a placebo, followed by Deucravacitinib, to evaluate its effectiveness and safety.

Study Design: This is an interventional study with a randomized, parallel assignment. It employs a quadruple masking method, meaning that the participant, care provider, investigator, and outcomes assessor are unaware of the group assignments. The primary purpose of the study is treatment-focused.

Study Timeline: The study began on September 11, 2023, with an expected primary completion date in the future. The last update was submitted on June 27, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.

Market Implications: The update on this study could positively influence Bristol-Myers Squibb’s stock performance by demonstrating their commitment to innovative treatments in the autoimmune space. Successful results could enhance investor sentiment and position the company favorably against competitors in the pharmaceutical industry.

The study is ongoing, and further details are available on the ClinicalTrials portal.